SAN DIEGO, Feb. 6, 2017 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of clinically
actionable liquid biopsy tests designed to improve the management
of cancer patients, announces that President and CEO Michael W. Nall will present a corporate
overview at the 19th Annual BIO CEO and Investor
Conference on Monday, February 13,
2017, at 2:00 p.m. Eastern
time (11:00 a.m. Pacific
time). The conference is being held at the Waldorf Astoria
New York hotel in New York
City.
A live webcast of the corporate presentation at the BIO CEO and
Investor Conference will be available on the Company's website at
ir.biocept.com. A replay of the webcast will be available for 90
days.
About BIO CEO and Investor Conference
The BIO CEO and Investor Conference is the largest investor
conference focused on established and emerging publicly traded and
select private biotech companies. The event features plenary
sessions, fireside chats, business roundtables, therapeutic
workshops, company presentations and One-on-One
PartneringTM meetings.
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its proprietary
liquid biopsy technology to provide physicians with clinically
actionable information for treating and monitoring patients
diagnosed with cancer. The Company's patented Target Selector™
liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. For additional
information, please visit www.biocept.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biocept-to-present-at-the-19th-annual-bio-ceo-and-investor-conference-300402176.html
SOURCE Biocept, Inc.